Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases.
Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.
It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial.
The company was founded in 2004 and is headquartered in Westminster, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | -0.14 Decreased by -53.89% | - |
| Feb 1, 24 | -0.08 Increased by +6.13% | - |
| Oct 18, 23 | -0.10 Increased by +38.25% | - |
| Jul 21, 23 | -0.10 Increased by +53.32% | - |
| Apr 24, 23 | -0.09 Increased by +83.64% | - |
| Feb 24, 23 | -0.08 Increased by +85.45% | - |
| Oct 28, 22 | -0.16 Increased by +51.52% | - |
| Aug 2, 22 | -0.22 Increased by +35.29% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.42 M Increased by +32.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -958.00 K Increased by +68.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -896.00 K Increased by +72.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -800.00 K Increased by +85.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.11 M Increased by +55.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -3.08 M Increased by +36.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -3.27 M Increased by +20.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -5.68 M Decreased by -10.75% | Decreased by N/A% Decreased by N/A% |